S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Log in
NYSE:PANA

Panacea Acquisition Stock Forecast, Price & News

$10.31
-0.73 (-6.61 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.09
Now: $10.31
$10.86
50-Day Range
$10.04
MA: $10.81
$11.80
52-Week Range
$9.55
Now: $10.31
$12.52
Volume372,461 shs
Average Volume367,102 shs
Market Capitalization$190.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Panacea Acquisition Corp., a blank check company, focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in San Francisco, California.

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1924th out of 1,926 stocks

Pharmaceutical Preparations Industry

772nd out of 772 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone415-966-0807
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$190.28 million
Next Earnings DateN/A
OptionableNot Optionable
$10.31
-0.73 (-6.61 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PANA News and Ratings via Email

Sign-up to receive the latest news and ratings for PANA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Panacea Acquisition (NYSE:PANA) Frequently Asked Questions

What stocks does MarketBeat like better than Panacea Acquisition?

Wall Street analysts have given Panacea Acquisition a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Panacea Acquisition wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Panacea Acquisition's key competitors?

Who are Panacea Acquisition's key executives?

Panacea Acquisition's management team includes the following people:
  • Mr. Oleg Nodelman, Chief Exec. Officer (Age 44)
  • Mr. Scott Eric Perlen, Chief Financial Officer (Age 46)
  • Mr. Scott Platshon, Chief Operating Officer (Age 30)
  • Ms. Caroline Stout, Chief Investment Officer (Age 30)
  • Ms. Sarah Marriott, Sec. & Director (Age 44)

What is Panacea Acquisition's stock symbol?

Panacea Acquisition trades on the New York Stock Exchange (NYSE) under the ticker symbol "PANA."

Who are Panacea Acquisition's major shareholders?

Panacea Acquisition's stock is owned by many different institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.22%).

Which major investors are buying Panacea Acquisition stock?

PANA stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC.

How do I buy shares of Panacea Acquisition?

Shares of PANA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Panacea Acquisition's stock price today?

One share of PANA stock can currently be purchased for approximately $10.31.

How big of a company is Panacea Acquisition?

Panacea Acquisition has a market capitalization of $190.28 million.

What is Panacea Acquisition's official website?

The official website for Panacea Acquisition is panacea.ecor1cap.com.

How can I contact Panacea Acquisition?

Panacea Acquisition's mailing address is 357 TEHAMA STREET FLOOR 3, SAN FRANCISCO CA, 94103. The company can be reached via phone at 415-966-0807 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.